
Cardiovascular Pharmaceutical Market in China 2021
- March 15, 2021
- Helix Strategy
- 40
Cardiovascular Pharmaceutical Market in China 2021
Abstract
The cardiovascular pharmaceutical market in China in terms of revenue is set to grow by US$ 7 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for cardiovascular pharmaceutical. The China cardiovascular pharmaceutical market is segmented on the basis of distribution channel, type. By distribution channel, it is categorized into hospital, and retail. By type, the cardiovascular pharmaceutical market is divided into biologics, chemical medicine, and traditional Chinese medicine.
The report has profiled some of the key players of the market such as Bayer AG, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Merck & Co., Novartis International AG, Pfizer Inc., Qilu Pharmaceutical Co. Ltd., Sanofi S.A., Shanghai Pharmaceuticals Holding Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cardiovascular pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Distribution channel: hospital, and retail
Type: biologics, chemical medicine, and traditional Chinese medicine
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China cardiovascular pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the cardiovascular pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
Content
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Cardiovascular Pharmaceutical Market by Distribution Channel
4.1 Hospital
4.2 Retail
5. Cardiovascular Pharmaceutical Market by Type
5.1 Biologics
5.2 Chemical Medicine
5.3 Traditional Chinese Medicine
6. Company Profiles
6.1 Bayer AG
6.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
6.3 Merck & Co.
6.4 Novartis International AG
6.5 Pfizer, Inc.
6.6 Qilu Pharmaceutical Co., Ltd.
6.7 Sanofi S.A.
6.8 Shanghai Pharmaceuticals Holding Co., Ltd.
6.9 Zhejiang Huahai Pharmaceutical Co., Ltd.
7. Appendix
7.1 About StrategyHelix
7.2 Disclaimer
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for cardiovascular pharmaceutical. The China cardiovascular pharmaceutical market is segmented on the basis of distribution channel, type. By distribution channel, it is categorized into hospital, and retail. By type, the cardiovascular pharmaceutical market is divided into biologics, chemical medicine, and traditional Chinese medicine.
The report has profiled some of the key players of the market such as Bayer AG, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Merck & Co., Novartis International AG, Pfizer Inc., Qilu Pharmaceutical Co. Ltd., Sanofi S.A., Shanghai Pharmaceuticals Holding Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cardiovascular pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Distribution channel: hospital, and retail
Type: biologics, chemical medicine, and traditional Chinese medicine
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China cardiovascular pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the cardiovascular pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Cardiovascular Pharmaceutical Market by Distribution Channel
4.1 Hospital
4.2 Retail
5. Cardiovascular Pharmaceutical Market by Type
5.1 Biologics
5.2 Chemical Medicine
5.3 Traditional Chinese Medicine
6. Company Profiles
6.1 Bayer AG
6.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
6.3 Merck & Co.
6.4 Novartis International AG
6.5 Pfizer, Inc.
6.6 Qilu Pharmaceutical Co., Ltd.
6.7 Sanofi S.A.
6.8 Shanghai Pharmaceuticals Holding Co., Ltd.
6.9 Zhejiang Huahai Pharmaceutical Co., Ltd.
7. Appendix
7.1 About StrategyHelix
7.2 Disclaimer
Send To A Friend
Related Report
China Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2026
- MarketLine
- February 10, 2023
- 0.00
2023 China Coagulation Testing Market--Hemostasis Analyzers and Consumables--2022 Supplier Shares, 2022-2027 Segment Volume and Sales Forecasts for over 40 Coagulation Assays, Opportunities for Suppliers--Molecular, Chromogenic and Immunodiagnostic Hemostasis Tests--Growth Strategies, Latest Technologies, Instrumentation Pipeline
- VPG Market Research
- March 22, 2023
- 0.00
2023 China Breast Cancer Diagnostics Market--CEA, CA 15-3, CA 27.29,CA 125, Estrogen Receptor, HER2, Polypeptide-Specific Antigen, Progesterone Receptor--Country Database and Analysis--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Segment Forecasts, Emerging Technologies, Latest Instrumentation, Growth Opportunities
- VPG Market Research
- March 2, 2023
- 0.00
Research Report on China's Artificial Kidney Import 2023-2032
- China Research and Intelligence
- February 1, 2023
- 0.00
Research Report on China's Patient Monitor Export 2023-2032
- China Research and Intelligence
- February 1, 2023
- 0.00